However, PTX-mediated modulation of the TLR4 pathway is implicated in the activation of NF-κB and MAPK-related downstream signaling and subsequent release of pro-inflammatory molecules that enhance the progression of cancers and confer chemoresistance to drug intervention in cancers [105, 106]. Here, NFKB1 is linked to cancer.